Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Ugly sell-off hits British Biotech

March 16, 1998 8:00 AM UTC

OXFORD - Investors gave British Biotech (LSE:BBG; BBIOY) another hosing after it emerged that the company had suspended its director of clinical research, Andrew Millar, for alleged misconduct. When the dust settled at week's end, BBG's market value had been slashed by £128 million (US$209 million).

In a statement to the London Stock Exchange last Thursday, BBG announced that Millar, "has been suspended pending an investigation of breaches of company policy."...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article